Loading organizations...
Azura Ophthalmics Limited has raised $56.0M across 3 funding rounds.
Key people at Azura Ophthalmics Limited.
Azura Ophthalmics Limited has raised $56.0M in total across 3 funding rounds.
Azura Ophthalmics Limited is a clinical-stage biopharmaceutical company developing ophthalmic keratolytics to treat ocular surface diseases, operating primarily out of Melbourne, Australia, and Tel Aviv, Israel. The pre-revenue biotechnology firm focuses on therapies like its lead candidate, AZR-MD-001, designed to treat Meibomian Gland Dysfunction (MGD), restore gland function, improve contact lens wear time, and alleviate symptoms of dry eye disease. Operating with an estimated 10 to 50 employees, the enterprise has secured approximately AU $108 million in total venture capital funding to advance its Phase 2b clinical trials, which includes a $16 million Series B round. The company's ongoing clinical development and research operations are financially backed by prominent institutional investors, including OrbiMed, TPG Biotech, Brandon Capital, and Ganot Capital. Azura Ophthalmics Limited was originally founded in 2014 by Yair Alster, Omer Rafaeli, and Charles Bosworth.
Azura Ophthalmics Limited has raised $56.0M in total across 3 funding rounds.
Azura Ophthalmics Limited's investors include Brandon Capital, Ganot Capital, OrbiMed, TPG Biotech, 5AM Ventures, Brandon Capital Partners, Ed Mathers, Chris Nave, Anat Naschitz, Heather Preston, Guy Katsav.
Key people at Azura Ophthalmics Limited.
Azura Ophthalmics Limited is a clinical-stage biotechnology company developing a first‑in‑class class of *ophthalmic keratolytics* aimed at treating meibomian gland dysfunction (MGD), dry eye disease and other lid‑margin/ocular surface disorders by addressing core pathophysiology rather than only symptoms[2][4].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Health Landscape
Quick Take & Future Outlook
Core sources: Azura’s company website and “About Us” materials, investor/portfolio pages (Brandon Capital), and clinical/patent pipeline summaries (PatSnap / IVC data) provide the basis for the above profile[2][3][1].
Azura Ophthalmics Limited has raised $56.0M across 3 funding rounds. Most recently, it raised $20.0M Azura Ophthalmics - Other Equity in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 22, 2020 | $20M Venture Round | Brandon Capital, Ganot Capital, OrbiMed, TPG Biotech | — | Announced |
| Oct 1, 2020 | $20M Series C | — | 5AM Ventures, Brandon Capital Partners, ED Mathers | Announced |
| Oct 1, 2017 | $16M Series B | Chris Nave, Anat Naschitz, Heather Preston | 5AM Ventures, Brandon Capital Partners, ED Mathers, GUY Katsav | Announced |